ArticleAdvanced pharmaceutical bulletin2017
Strategies for Improving siRNA-Induced Gene Silencing Efficiency.
Article in Advanced pharmaceutical bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- RNAi-based therapeutics targeting the F gene in human metapneumovirus: An in-silico approach.Journal, genetic engineering & biotechnology · 2026Article
- AAV-Delivered RNAi Targeting Mutant LDB3 Prevents and Reverses Myofibrillar Myopathy through Mechanosignaling Restoration.bioRxiv : the preprint server for biology · 2026Article
- Two-Stage Probability-Enhanced Regression on Property Matrices and LLM Embeddings Enables State-of-the-Art Prediction of Gene Knockdown by Modified siRNAs.International journal of molecular sciences · 2025Article
- siRNADiscovery: a graph neural network for siRNA efficacy prediction via deep RNA sequence analysis.Briefings in bioinformatics · 2024Article
- Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.Frontiers in molecular biosciences · 2024Review
- Therapeutic siRNA: State-of-the-Art and Future Perspectives.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Mesoporous silica-coated silver nanoparticles as ciprofloxacin/siRNA carriers for accelerated infected wound healing.Journal of nanobiotechnology · 2022Article
- In Silico Design of siRNAs for Silencing CLEC5A Receptor as a Potential Therapeutic Approach Against Dengue and Japanese Encephalitis Virus Infection in Human.Bioinformatics and biology insights · 2022Article
- TREAT: Therapeutic RNAs exploration inspired by artificial intelligence technology.Computational and structural biotechnology journal · 2022Article
- In Vitro Methods to Decipher the Structure of Viral RNA Genomes.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.Brain and behavior · 2021Review
- A cassava common mosaic virus vector for virus-induced gene silencing in cassava.Plant methods · 2021Article
- Multiplex Genome Editing in Chinese Hamster Ovary Cell Line Using All-in-One and HITI CRISPR Technology.Advanced pharmaceutical bulletin · 2021Article
- Caspase-7 deficiency in Chinese hamster ovary cells reduces cell proliferation and viability.Biological research · 2020Article
- CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.Cellular and molecular neurobiology · 2020Review
- CRISPR Cpf1 proteins: structure, function and implications for genome editing.Cell & bioscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.